PRESSEMITTEILUNGEN

Paris, Frankreich – 16. November 2009 – (ots) – Das RealiseAF-Register wird dazu beitragen, das kardiovaskuläre Risikoprofil von Vorhofflimmerpatienten besser zu definieren und zu verstehen sowie kardiovaskuläre Folgen besser zu charakterisieren
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) gab heute den Start des RealiseAF-Registers bekannt (Real life global Survey Evaluating patients with Atrial Fibrillation), einem internationalen [...]

Continue reading

16 November, Asien, Europa, Fibrillation, Frankreich, Global Survey, Investitionen, Jean Pierre, Lateinamerika, Lehner, Medical Officer, Mehr Als, Mit, Nyse, Ots, Paris, Population, Sanofi Aventis, Sny, Vhf

Paris, November 16 (ots/PRNewswire) – – The RealiseAF Registry Will Help to Better Define and Understand the Cardiovascular Risk Profile of AF Patients and Characterize Their Cardiovascular Outcomes
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today the launch of the RealiseAF registry (Real Life global Survey Evaluating patients with Atrial Fibrillation), an international, [...]

Continue reading

America Asia, Atrial Fibrillation, Broad Spectrum, Cardiovascular Outcomes, Cardiovascular Risk, Global Burden, Global Survey, Health Burden, Hopital Bichat, Lehner, Medical Officer, North Africa, Prnewswire, Risk Profile, Risk Profiles, Sanofi Aventis, Sny, Therapeutic Solutions, Transient Causes, True Impact

Paris (ots/PRNewswire) – – 76% Higher Dose of Insulin detemir Needed to Achieve Similar, Well Tolerated Glycemic Control Versus Lantus(R)
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a head-to-head study providing further evidence on the efficacy of once-daily, 24-hour basal insulin Lantus(R) (insulin glargine [rDNA] injection) compared to twice-daily insulin detemir. The [...]

Continue reading

Clinical Trial, Daily Dose, Easd, Efficacy, Endpoint, Euronext, European Association For The Study Of Diabetes, Hba1c, Hypoglycaemia, Inferiority, Insulin Detemir, Insulin Glargine, Insulin Lantus, Lantus, Lantus Insulin, Multimedia News, Nyse, Ots, Sanofi Aventis, Sny

Paris (ots/PRNewswire) – Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq(R) (dronedarone – 400mg Tablets).
The CHMP has recommended the approval of [...]

Continue reading

Cardiovascular Complications, Chmp, Dronedarone, Emea, Endpoint, Euronext, European Medicines, Hospitalization, Lehner, Medical Officer, Medicines Agency, Multaq, Nyse, Ots, Prnewswire, Recent History, Recurrence, Sanofi Aventis, Sny, Stable Patients

Paris (ots/PRNewswire) – – Multaq(R) Approved to Reduce the Risk of Cardiovascular Hospitalization in Patients With Atrial Fibrillation or Atrial Flutter
- U.S Commercial Launch Planned for the Summer of 2009
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq(R) (dronedarone) 400 mg Tablets. Patients [...]

Continue reading

Atrial Fibrillation, Atrial Flutter, Cardiovascular Risk Factors, Clinical Benefit, Current Management, Dronedarone, Ejection Fraction, Euronext, Food And Drug Administration, Food And Drug Administration Fda, Hospitalization, Launch, Mg Tablets, Multaq, Nyse, Prnewswire, Sanofi Aventis, Sinus Rhythm, Sny, Treatment Option

Paris and Brisbane, California (ots/PRNewswire) – – Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with [...]

Continue reading

Breast Cancer, Brisbane California, Cancer Drug, Carboplatin, Clinical Benefit, Disease Progression, Dna Damage, Free Survival, Gemcitabine, Investigational Agent, Lacking Expression, Metastatic Breast Cancer, Overexpression, Partial Response, Prnewswire, Progesterone Receptors, Sanofi Aventis, Sny, Stable Disease, Tumor Response

Paris (ots/PRNewswire) – – Multaq(R) (dronedarone) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation
Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) announced today that the ATHENA trial was published in the New England Journal of Medicine. The trial showed that Multaq(R) (dronedarone), [...]

Continue reading

Athena, Atrial Fibrillation, Dronedarone, England Journal Of Medicine, Euronext, Hospitalization, Journal Of Medicine, Landmark, Medicine, Multaq, New England, New England Journal, New England Journal Of Medicine, New Medicine, Nyse, Ots, Paris Bourse, Prnewswire, Sanofi Aventis, Sny

Paris, Frankreich (ots) -
– Dronedaron reduziert das Risiko für kardiovaskulär bedingte
Krankenhausaufenthalte oder Tod bei Patienten mit Vorhofflimmern
signifikant um 24 Prozent –
Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) gab heute bekannt, dass die ATHENA Studie im New England Journal of [...]

Continue reading

Athena, England Journal Of Medicine, Ergebnisse Der, Euronext, Frankreich, Journal Of Medicine, Medicine, Mit, New England, New England Journal, New England Journal Of Medicine, New Medicine, Nyse, Ots, Paris Bourse, Risiko, Sanofi Aventis, Sny, Vhf